embed embed share link link comment comment
" type="application/x-shockwave-flash" allowfullscreen="true" width="425" height="344">
Embed This Video close
Share This Video close
bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark
embed test
Rate This Video embed
1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...
Tags For This Video tags
rate rate tags tags related related lights lights

J&J CFO: Not-for-Profit Vaccine Price Likely to End in 2021

Johnson & Johnson CFO Joseph Wolk discusses the efficacy of the company’s Covid-19 vaccine against the delta variant, second-quarter results, and efforts to address damage claims over its talcum-based baby powder. He speaks on “Bloomberg Markets.”